Atossa Therapeutics, Inc. ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, today announced ...
The SERD improved survival endpoints compared to standard adjuvant endocrine therapy in a Phase III trial that may support ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback